What Is Drug-Resistant Epilepsy and When Is Surgery Considered?
Drug-resistant epilepsy is defined as failure to control seizures despite two appropriately chosen and adequately dosed antiseizure medications. At this point the chance that a third or fourth drug will achieve freedom from seizures falls markedly; for this reason international guidelines recommend referring resistant patients to an epilepsy centre. Surgery carries a high chance of success particularly when seizures arise from a single, removable region of the brain — for example a structural focus such as mesial temporal sclerosis (hippocampal sclerosis), cortical dysplasia, a benign tumour or a cavernoma. The goal is not merely to reduce seizures but, where possible, to stop them completely and to improve the patient's quality of life, education and work, and safety. Untreated drug-resistant epilepsy carries risks of fall injuries, cognitive impact and sudden unexpected death (SUDEP); surgical evaluation should therefore not be delayed.
Comprehensive Pre-Surgical Evaluation
The foundation of epilepsy surgery is safely identifying the region where seizures begin (the epileptogenic focus); this is done not by a single test but by complementary investigations. Standard steps include long-term video-EEG monitoring (EEG and clinical recording of seizures), high-resolution epilepsy-protocol MRI, neuropsychological assessment and, where needed, PET, SPECT, magnetoencephalography (MEG) and functional MRI. To determine which hemisphere holds functions such as speech and memory, a Wada test or functional mapping is used in some cases. If the focus cannot be fully defined by non-invasive studies, invasive recording with electrodes placed in or on the brain (stereo-EEG / subdural grids) may be required. All of this data is evaluated together at an epilepsy board (neurologist, neurosurgeon, neuroradiologist, neuropsychologist); the decision is the team's joint conclusion, not that of a single physician.
Surgical Methods: Resective, Disconnective and Neuromodulation
Epilepsy surgery is not a single operation; different methods are used according to the location and type of focus. In resective surgery the seizure-generating tissue is removed — the most common, temporal lobectomy/amygdalohippocampectomy, is known for high seizure-freedom rates in mesial temporal sclerosis; in lesional epilepsy (tumour, dysplasia, cavernoma) removing the focal lesion treats both the seizures and the underlying disease. In disconnective methods tissue is not removed but the pathways of seizure spread are cut (callosotomy, hemispherotomy) — especially in widespread or single-hemisphere severe paediatric epilepsies. When the focus lies in too critical an area to remove, or there are multiple foci, neuromodulation comes in: vagus nerve stimulation (VNS), deep brain stimulation (DBS) and responsive neurostimulation (RNS) can reduce seizure frequency, but generally aim for marked reduction rather than freedom from seizures. Which method is appropriate is entirely individual; there is no standard prescription.
The Surgical Process and Recovery
Once a decision is made, surgery is planned according to the location of the focus. Resective surgery is performed under general anaesthesia, with awake craniotomy where the focus lies near a functional area; neuronavigation and, where needed, intraoperative electrocorticography (ECoG) are used. The procedure typically takes 3–6 hours; afterwards there is usually 1 day of intensive care and a total hospital stay of 3–6 days. Neuromodulation procedures such as VNS are smaller interventions requiring a shorter stay. Antiseizure medications are not stopped immediately after surgery; after a period of observed seizure freedom, the team may plan a gradual reduction. Recovery is completed with a return to daily life within 4–6 weeks in most patients, although the durability of seizure control becomes clear over months. Neuropsychological follow-up, especially for memory and language, is important for before-and-after comparison.
Risks and Realistic Expectations
Epilepsy surgery, while effective in well-selected patients, is not without risk and these must be discussed honestly: general surgical risks (bleeding, infection), temporary or permanent changes in memory, language or visual field depending on the location of the focus, and mood fluctuations. These risks are markedly reduced by comprehensive preoperative mapping. Outcomes depend on the type of focus: in mesial temporal sclerosis seizure-freedom rates are high in well-selected patients; in lesional epilepsy complete removal of the lesion gives strong results; in multifocal or widespread epilepsy neuromodulation usually provides meaningful reduction rather than freedom from seizures. A 'guaranteed freedom from seizures' is never promised; expectations are shared openly with the patient and family according to the evaluation. For patients who are not surgical candidates, options such as modern drug combinations and the ketogenic diet are also considered — not everyone needs surgery.